GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.50M | -59.15M | -57.09M | -37.83M | -38.13M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.60M | 45.25M | 45.10M | 27.80M | 27.56M |
| Change in Net Operating Assets | 1.47M | 713.00K | -920.00K | -1.33M | 149.00K |
| Cash from Operations | -14.43M | -13.18M | -12.91M | -11.36M | -10.42M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 1.00K | 0.00 |
| Cash from Investing | -- | -- | -- | 1.00K | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.02M | 5.46M | 5.50M | 1.05M | 1.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 9.37M | 14.51M | 10.51M | 6.50M | 5.44M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -229.00K | -229.00K | -229.00K | -85.00K | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14.16M | 19.74M | 15.78M | 7.47M | 6.49M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -267.00K | 6.56M | 2.86M | -3.89M | -3.93M |